

Joan Seoane

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5526175/publications.pdf>

Version: 2024-02-01

106
papers

15,971
citations

43973

48
h-index

39575

94
g-index

111
all docs

111
docs citations

111
times ranked

24924
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual inhibition of TGF β 2 and PD β 1: a novel approach to cancer treatment. <i>Molecular Oncology</i> , 2022, 16, 2117-2134.	2.1	53
2	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2022, 24, 855-871.	0.6	38
3	Cerebrospinal fluid liquid biopsies for medulloblastoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 73-74.	12.5	0
4	Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis. <i>Cancer Research</i> , 2022, 82, 2552-2564.	0.4	6
5	Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. <i>Haematologica</i> , 2021, 106, 513-521.	1.7	75
6	WORLD CANCER RESEARCH DAY: A Call to Action for a Coordinated International Research Effort to Prevent, Diagnose, and Treat Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 963-966.	3.2	5
7	Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. <i>Nature Communications</i> , 2021, 12, 1503.	5.8	45
8	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , 2021, 299, 109-119.	3.6	54
9	ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer. <i>Cancers</i> , 2021, 13, 1989.	1.7	26
10	A single-cell tumor immune atlas for precision oncology. <i>Genome Research</i> , 2021, 31, 1913-1926.	2.4	87
11	Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition. <i>Journal of Neuro-Oncology</i> , 2020, 149, 13-25.	1.4	11
12	Clinical development of therapies targeting TGF β 2: current knowledge and future perspectives. <i>Annals of Oncology</i> , 2020, 31, 1336-1349.	0.6	157
13	Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma. <i>Nature Communications</i> , 2020, 11, 5376.	5.8	67
14	Cerebrospinal fluid circulating tumour DNA as a liquid biopsy for central nervous system malignancies. <i>Current Opinion in Neurology</i> , 2020, 33, 736-741.	1.8	4
15	The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	46
16	Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. <i>Cancer Letters</i> , 2020, 480, 24-28.	3.2	33
17	Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures. <i>Frontiers in Immunology</i> , 2020, 11, 605170.	2.2	101
18	How liquid biopsies can change clinical practice in oncology. <i>Annals of Oncology</i> , 2019, 30, 1580-1590.	0.6	231

#	ARTICLE	IF	CITATIONS
19	Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. <i>Acta Neuropathologica</i> , 2019, 138, 1053-1074.	3.9	106
20	LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy. <i>Nature Communications</i> , 2019, 10, 2416.	5.8	150
21	The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer. <i>Cell Reports</i> , 2019, 27, 2690-2708.e10.	2.9	95
22	Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. <i>Annals of Oncology</i> , 2019, 30, 211-218.	0.6	96
23	Abstract CN08-03: LIF in cancer. , 2019, , .		0
24	Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. <i>Clinical Cancer Research</i> , 2018, 24, 2812-2819.	3.2	128
25	Early evolutionary divergence between papillary and anaplastic thyroid cancers. <i>Annals of Oncology</i> , 2018, 29, 1454-1460.	0.6	44
26	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. <i>Oncotarget</i> , 2018, 9, 20617-20630.	0.8	36
27	p95HER2 α T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	59
28	The right compound for the right target: tackling RET. <i>Annals of Oncology</i> , 2018, 29, 1623-1625.	0.6	5
29	Subjugation of TGF β 2 Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining. <i>Clinical Cancer Research</i> , 2018, 24, 6001-6014.	3.2	71
30	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. <i>Journal of Clinical Investigation</i> , 2018, 128, 3887-3905.	3.9	79
31	The integrated genomic and immune landscapes of lethal metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1009-1009.	0.8	2
32	A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS2602-TPS2602.	0.8	4
33	Abstract LB-B34: LIF as a novel cancer immunotherapy target: modulating the tumor microenvironment with MSC-1, a humanized anti-LIF monoclonal antibody. , 2018, , .		0
34	Interrogating open issues in cancer precision medicine with patient-derived xenografts. <i>Nature Reviews Cancer</i> , 2017, 17, 254-268.	12.8	527
35	TGF- β 2 Family Signaling in Tumor Suppression and Cancer Progression. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a022277.	2.3	345
36	Division hierarchy leads to cell heterogeneity. <i>Nature</i> , 2017, 549, 164-166.	13.7	14

#	ARTICLE	IF	CITATIONS
37	An antisense oligonucleotide targeting TGF- β 2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages. <i>Annals of Oncology</i> , 2017, 28, 2278-2285.	0.6	25
38	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). <i>Annals of Translational Medicine</i> , 2017, 5, 390-390.	0.7	0
39	The Taming of the TAMs. <i>Trends in Cell Biology</i> , 2016, 26, 562-563.	3.6	8
40	Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer. <i>Drugs in Context</i> , 2016, 5, 1-8.	1.0	2
41	USP15 regulates SMURF2 kinetics through C-lobe mediated deubiquitination. <i>Scientific Reports</i> , 2015, 5, 14733.	1.6	50
42	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. <i>Nature Communications</i> , 2015, 6, 8839.	5.8	605
43	Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor- β 2 receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. <i>Investigational New Drugs</i> , 2015, 33, 357-370.	1.2	90
44	First-in-Human Dose Study of the Novel Transforming Growth Factor- β 2 Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 553-560.	3.2	199
45	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	7.7	821
46	Blockade of the SNARE Protein Syntaxin 1 Inhibits Glioblastoma Tumor Growth. <i>PLoS ONE</i> , 2015, 10, e0119707.	1.1	30
47	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. <i>Oncotarget</i> , 2015, 6, 37269-37280.	0.8	135
48	Genomic landscape of anaplastic thyroid cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 6033-6033.	0.8	0
49	Early drug development in advanced gynecologic cancer based on genetic tumor profiling. <i>Journal of Clinical Oncology</i> , 2015, 33, 5562-5562.	0.8	0
50	Abstract 930: Analysis of cell-free tumor DNA in cerebrospinal fluid to characterize and monitor the genetic alterations of brain tumors. <i>Cancer Research</i> , 2015, 75, 930-930.	0.4	2
51	Cross-Talk Between the Notch and Transforming Growth Factor- β (Tgf- β ;) Signaling Pathways in Glioma Initiating Cells (Gics). <i>Annals of Oncology</i> , 2014, 25, iv139.	0.6	0
52	Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. <i>Nature Communications</i> , 2014, 5, 4632.	5.8	144
53	Active CREB1 Promotes a Malignant TGF β 2 Autocrine Loop in Glioblastoma. <i>Cancer Discovery</i> , 2014, 4, 1230-1241.	7.7	63
54	Glioblastoma Multiforme: A Look Inside Its Heterogeneous Nature. <i>Cancers</i> , 2014, 6, 226-239.	1.7	177

#	ARTICLE	IF	CITATIONS
55	The challenge of intratumour heterogeneity in precision medicine. <i>Journal of Internal Medicine</i> , 2014, 276, 41-51.	2.7	66
56	Escaping Out of the Brain. <i>Cancer Discovery</i> , 2014, 4, 1259-1261.	7.7	12
57	Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. <i>Cancer Discovery</i> , 2014, 4, 998-1013.	7.7	1,341
58	Gremlins Sabotage the Mechanisms of Cancer Stem Cell Differentiation. <i>Cancer Cell</i> , 2014, 25, 716-717.	7.7	10
59	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. <i>Annals of Oncology</i> , 2014, 25, 1729-1735.	0.6	308
60	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing. <i>Molecular Oncology</i> , 2014, 8, 150-158.	2.1	37
61	New approach to cancer therapy based on a molecularly defined cancer classification. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 70-74.	157.7	22
62	Brain metastasis: New opportunities to tackle therapeutic resistance. <i>Molecular Oncology</i> , 2014, 8, 1120-1131.	2.1	37
63	Relevance of IGFBP2 proteolysis in glioma and contribution of the extracellular protease ADAMTS1. <i>Oncotarget</i> , 2014, 5, 4295-4304.	0.8	10
64	Circulating tumour cells and cell-free DNA as tools for managing breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 377-389.	12.5	164
65	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <i>HER2</i> V659E Mutation. <i>Cancer Discovery</i> , 2013, 3, 1238-1244.	7.7	43
66	Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF- β) receptor I kinase inhibitor, LY2157299 monohydrate (LY).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2016-2016.	0.8	12
67	Abstract PD4-5: Longitudinal massively parallel sequencing analysis of circulating cell-free tumor DNA: A feasibility study. , 2013, , .		0
68	400 CREB Regulates the Autocrine Induction of TGF- β 2 by TGF- β 1 in Glioblastoma. <i>European Journal of Cancer</i> , 2012, 48, S97.	1.3	1
69	407 Nur77 is a Tumor Suppressor That Mediates P53 Antioncogenic Activities. <i>European Journal of Cancer</i> , 2012, 48, S98.	1.3	0
70	417 Exploring TRIM59 Oncogenic Function. <i>European Journal of Cancer</i> , 2012, 48, S101.	1.3	0
71	859 TGF- β Inhibits TMEFF2 Expression in Glioma Cells. <i>European Journal of Cancer</i> , 2012, 48, S207.	1.3	0
72	900 FoxG1 Confers Resistance to PI3K Inhibitors Through the Repression of FoxO Activity. <i>European Journal of Cancer</i> , 2012, 48, S218.	1.3	0

#	ARTICLE	IF	CITATIONS
73	Noncyclam Tetraamines Inhibit CXC Chemokine Receptor Type 4 and Target Glioma-Initiating Cells. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7560-7570.	2.9	10
74	USP15 stabilizes TGF- β 2 receptor I and promotes oncogenesis through the activation of TGF- β 2 signaling in glioblastoma. <i>Nature Medicine</i> , 2012, 18, 429-435.	15.2	342
75	Circulating tumour cells in early breast cancer. <i>Lancet Oncology</i> , The, 2012, 13, e370.	5.1	2
76	The oral transforming growth factor-beta (TGF- β) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2042-2042.	0.8	5
77	TGF- β 2 Receptor Inhibitors Target the CD44 ^{high} /Id1 ^{high} Glioma-Initiating Cell Population in Human Glioblastoma. <i>Cancer Cell</i> , 2010, 18, 655-668.	7.7	534
78	NO Signals from the Cancer Stem Cell Niche. <i>Cell Stem Cell</i> , 2010, 6, 97-98.	5.2	1
79	TGF- β 2 and cancer initiating cells. <i>Cell Cycle</i> , 2009, 8, 3787-3788.	1.3	7
80	Identification of multipotent mesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis. <i>Experimental Cell Research</i> , 2009, 315, 3004-3013.	1.2	30
81	TGF- β 2 Increases Glioma-Initiating Cell Self-Renewal through the Induction of LIF in Human Glioblastoma. <i>Cancer Cell</i> , 2009, 15, 315-327.	7.7	489
82	The TGF- β pathway as a therapeutic target in cancer. <i>Clinical and Translational Oncology</i> , 2008, 10, 14-19.	1.2	48
83	The TGF-beta pathway in cancer. <i>European Journal of Cancer</i> , Supplement, 2008, 6, 121.	2.2	0
84	TGF- β 2 signalling-related markers in cancer patients with bone metastasis. <i>Biomarkers</i> , 2008, 13, 217-236.	0.9	60
85	Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235. <i>Cancer Research</i> , 2008, 68, 9221-9230.	0.4	474
86	TGF- β 2 Signaling in Homeostasis and Cancer. , 2008, , 23-35.		0
87	High TGF- β 2-Smad Activity Confers Poor Prognosis in Glioma Patients and Promotes Cell Proliferation Depending on the Methylation of the PDGF-B Gene. <i>Cancer Cell</i> , 2007, 11, 147-160.	7.7	446
88	Escaping from the TGF- β anti-proliferative control. <i>Carcinogenesis</i> , 2006, 27, 2148-2156.	1.3	136
89	A FoxO-Smad synexpression group in human keratinocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 12747-12752.	3.3	221
90	Smad transcription factors. <i>Genes and Development</i> , 2005, 19, 2783-2810.	2.7	2,063

#	ARTICLE	IF	CITATIONS
91	Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: A mechanistic based anti-tumor strategy. <i>Journal of Clinical Oncology</i> , 2005, 23, 3112-3112.	0.8	32
92	p21WAF1/Cip1 at the Switch Between the Anti-Oncogenic and Oncogenic Faces of TGF-beta. <i>Cancer Biology and Therapy</i> , 2004, 3, 226-227.	1.5	18
93	Opposite Smad and Chicken Ovalbumin Upstream Promoter Transcription Factor Inputs in the Regulation of the Collagen VII Gene Promoter by Transforming Growth Factor- β^2 . <i>Journal of Biological Chemistry</i> , 2004, 279, 23759-23765.	1.6	18
94	Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation. <i>Cell</i> , 2004, 117, 211-223.	13.5	903
95	Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. <i>Nature</i> , 2002, 419, 729-734.	13.7	618
96	Crystal Structure of a Phosphorylated Smad2. <i>Molecular Cell</i> , 2001, 8, 1277-1289.	4.5	271
97	Repression of p15INK4b expression by Myc through association with Miz-1. <i>Nature Cell Biology</i> , 2001, 3, 392-399.	4.6	504
98	TGF β^2 influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. <i>Nature Cell Biology</i> , 2001, 3, 400-408.	4.6	448
99	The Role of the Regulatory Protein of Glucokinase in the Glucose Sensory Mechanism of the Hepatocyte. <i>Journal of Biological Chemistry</i> , 2000, 275, 10597-10603.	1.6	92
100	OAZ Uses Distinct DNA- and Protein-Binding Zinc Fingers in Separate BMP-Smad and Olf Signaling Pathways. <i>Cell</i> , 2000, 100, 229-240.	13.5	399
101	Glucokinase Overexpression Restores Glucose Utilization and Storage in Cultured Hepatocytes from Male Zucker Diabetic Fatty Rats. <i>Journal of Biological Chemistry</i> , 1999, 274, 31833-31838.	1.6	34
102	Myc Downregulation by Transforming Growth Factor β^2 Required for Activation of the p15 ^{Ink4b} G ₁ Arrest Pathway. <i>Molecular and Cellular Biology</i> , 1999, 19, 5913-5922.	1.1	214
103	Metabolic Impact of Adenovirus-mediated Overexpression of the Glucose-6-phosphatase Catalytic Subunit in Hepatocytes. <i>Journal of Biological Chemistry</i> , 1997, 272, 26972-26977.	1.6	72
104	Bridging the gap between glucose phosphorylation and glycogen synthesis in the liver. <i>Biochemical Society Transactions</i> , 1997, 25, 157-160.	1.6	20
105	Differential Metabolic Effects of Adenovirus-mediated Glucokinase and Hexokinase I Overexpression in Rat Primary Hepatocytes. <i>Journal of Biological Chemistry</i> , 1996, 271, 20524-20530.	1.6	82
106	Glucose 6-Phosphate Produced by Glucokinase, but Not Hexokinase I, Promotes the Activation of Hepatic Glycogen Synthase. <i>Journal of Biological Chemistry</i> , 1996, 271, 23756-23760.	1.6	102